Zevra, Priority-Review Voucher

Zevra sells priority review voucher for $150m to support drug launches
Zevra has sold its US Food and Drug Administration (FDA) priority review voucher (PRV) for $150m to an undisclosed party. The US-based company received the PRV when its Niemann-Pick disease type C drug Miplyffa (arimoclomol) won FDA approval in September 2024.
Zevra to net $150M from priority review voucher sale tied to Miplyffa approval
For Zevra Therapeutics, last year’s approval of the rare lysosomal storage disorder drug Miplyffa appears to be the gift that keeps on giving. | After receiving a rare pediatric disease priority review voucher in tandem with Miplyffa’s FDA green light in September,
Zevra Therapeutics to Sell Priority-Review Voucher for $150 Million
Zevra Therapeutics has inked a deal to sell its Food and Drug Administration priority-review voucher to an undisclosed buyer for gross proceeds of $150 million.
Zevra Therapeutics Enters Agreement to Sell its Rare Pediatric Disease Priority Review Voucher for $150 Million
LaDuane Clifton, Zevra’s Chief Financial Officer said, “This non-dilutive capital strengthens our balance sheet by adding gross cash proceeds of $150 million, supporting continued investment in our strategic priorities,
Zevra Therapeutics exec sells $23,587 in stock
Timothy J. Sangiovanni, Senior Vice President of Finance and Corporate Controller at Zevra Therapeutics Inc. (NASDAQ:ZVRA), has sold 3,000 shares of the company's common stock. The shares were sold at an average price of $7.
FiercePharma8h
Arrowhead, Zevra fire up campaigns for Rare Disease Day 2025
Zevra used the awareness day to roll out the “Learn NPC, Read Between the Signs” disease awareness campaign. The biotech won ...
Zevra Therapeutics to sell Rare Pediatric Disease PRV for $150M
Zevra Therapeutics (ZVRA) has entered into a definitive asset purchase agreement to sell its Rare Pediatric Disease Priority Review Voucher ...
The Pharma Letter1d
BRIEF—Zevra sells Miplyffa-linked PRV for $150 million
Rare disease-focused biopharma Zevra Therapeutics has agreed to sell its Rare Pediatric Disease Priority Review Voucher (PRV) to an undisclosed buyer for $150 million.
Investing1d
Zevra Therapeutics stock rises on $150M asset sale
Investing.com -- Shares of Zevra Therapeutics, Inc. ( Nasdaq: ZVRA) climbed 8% following the announcement that the company has entered into an agreement to sell its Rare Pediatric Disease Priority ...
Yahoo Finance1mon
Zevra Therapeutics to Participate at Upcoming Investor Conferences
CELEBRATION, Fla., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage rare disease therapeutics company, today announced that ...